6/17/2019  5:31:25 PM Chg. -0.360 Volume Bid5:31:25 PM Ask5:31:25 PM Market Capitalization Dividend Y. P/E Ratio
13.880CHF -2.53% 8,669
Turnover: 123,075.140
13.800Bid Size: 390 14.480Ask Size: 38 89.54 mill.CHF 0.00% -

Business description

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development of treatments for neuro-ophthalmological, neuromuscular and pulmonary diseases that currently lack treatment options, such as Leber's hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (DMD), congenital muscular dystrophy (CMD) and cystic fibrosis (CF). Santhera's lead product Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein, Serbia and Israel for the treatment of Leber's hereditary optic neuropathy (LHON) and is currently commercialized in more than 20 countries. Santhera is currently conducting the Phase III SIDEROS trial with Raxone® in patients with Duchenne muscular dystrophy (DMD) in respiratory function decline. In collaboration with the U.S. National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone® in a third indication, primary progressive multiple sclerosis (PPMS), and another product – omigapil – for congenital muscular dystrophy (CMD), both also areas of high unmet medical need.
 

Management board & Supervisory board

CEO
Thomas Meier
Management board
Christoph Rentsch, Günther Metz, Kristina Sjöblom Nygren, Oliver Strub
Supervisory board
Elmar Schnee, Martin Gertsch, Patrick Vink, Philipp Gutzwiller, Thomas Meier
 

Company data

Name: Santhera Pharmaceuticals AG
Address: Hohenrainstrasse 24,CH-4133 Pratteln
Phone: +41-61-9068950
Fax: +41-61-9068951
E-mail: office@santhera.com
Internet: www.santhera.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 52.85%
IPO date: -

Investor relations

Name: Thomas Meier
IR phone: +41-61-9068964
IR-Fax: -
IR e-mail: thomas.meier@santhera.com

Main Shareholders

Freefloat
 
52.85%
Idorsia Pharmaceuticals Ltd
 
13.28%
Waypoint Growth LP
 
8.36%
Aktionärsbindungsvertrag - Ernesto Bertarelli, Donata Guichard-Bertarelli - WDI Invest L.P.
 
7.12%
Iglu Group AG
 
4.23%
RENAISSANCE TECHNOLOGIES LLC - GF Trading LLC
 
2.99%
Polyphor AG
 
2.81%
Roderick Wong - RTW Master Fund
 
2.79%
Consonance Capital Master Account L.P.,
 
2.74%
Others
 
2.83%